Trial results

$CRVS — soquelitinib

Corvus Pharmaceuticals, Inc. (CRVS) soquelitinib: trial results in atopic dermatitis, 2027.

Research by Catalyst Intel

The catalyst

"Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027"

— Corvus Pharmaceuticals, 8-K filed 2026-11-05 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

CRVS-SOQUELITINIB-2026

Company

Corvus Pharmaceuticals, Inc.

Kind

Trial results

Indication

atopic dermatitis

Window

2027-03-01 – 2027-03-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.